ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ADMA Biologics, Inc. (ADMA) Q2 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brad Tade - Vice President, Financial Operations Conference Call Participants Anthony Petrone - Mizuho Americas Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 08, 2024. At this time, all participants are in a listen-only mode.
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know
In the latest trading session, Adma Biologics (ADMA) closed at $12.28, marking a +0.82% move from the previous day.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Adma Biologics (ADMA) closed at $12.18, marking a -1.46% move from the previous day.
ADMA Biologics: A Compelling GARP Stock For Biotech Investors
ADMA Biologics focuses on developing and commercializing plasma-derived products, primarily targeting immune-compromised patients. Revenue streams come from FDA-approved products, immunotechnology, and CDMO services, with a promising US immunoglobulin market. The company's IP portfolio includes three FDA-approved drugs: Asceniv, Bivigam, and Nabi-HB.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
Adma Biologics (ADMA) reachead $13.05 at the closing of the latest trading day, reflecting a -1.81% change compared to its last close.
